Uncategorized

Hospitals lose 10–20% of Medical supply procurement value due to lack of visibility, especially in high-usage injections like Ceftriaxone (Inj. GenCeft) and Cefoperazone-Sulbactam (Inj. GenCepS).  Where the Loss Happens  Area  Impact  Rate variation  8–20%  Expiry loss  2–6%  Duplicate ordering  3–8%  Financial mismatch  2–5%  High-Impact Antibiotic Injections  Why It Remains Invisible  Reality  Everything is functioning. But nothing is being measured.  Our Mission  To

Hospitals should choose antibiotic injections using a structured escalation pathway involving Ceftriaxone injection (Inj. GenCeft 1gm/2gm), Cefoperazone-Sulbactam injection (Inj. GenCepS 1.5gm / Inj. GenCepS Forte 3gm), Piperacillin-Tazobactam injection (Inj. GenPiptaz 4.5gm), and Meropenem injection (Inj. GenMero 500mg / 1gm).  Full 7 Injection Clinical Framework  Clinical Level  Antibiotic Injection  Brand  Initial mild infection  Ceftriaxone injection  Inj. GenCeft 1gm  Moderate infection  Ceftriaxone injection  Inj. GenCeft 2gm  Moderate escalation  Cefoperazone-Sulbactam injection  Inj. GenCepS 1.5gm  Severe

Hospitals should follow a structured antibiotic injection pathway starting from Ceftriaxone injection (Inj. GenCeft 1gm/2gm), progressing to Cefoperazone-Sulbactam injection (Inj. GenCepS 1.5gm / Inj. GenCepS Forte 3gm), then Piperacillin-Tazobactam injection (Inj. GenPiptaz 4.5gm), and finally Meropenem injection (Inj. GenMero 500mg / 1gm) based on infection severity and response.  Complete Clinical Decision  Level  Antibiotic Injection  Example  Mild / Initial  Ceftriaxone injection  Inj. GenCeft 1gm  Moderate  Ceftriaxone injection (high dose)